Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II)

NCT01252732 is registered in ClinicalTrials.gov with Melinta Therapeutics, Inc. as lead sponsor.

NCT NCT01252732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01252732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Single-Dose IV Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (SOLO II)
Lead sponsor
Melinta Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2010
Completion date
June 30, 2013
Enrollment
1,019 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abscess, cellulitis, systemic inflammation, wound infection